COMMUNIQUÉS West-GlobeNewswire

InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
27/07/2026
BEIJING, July 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its novel TYK2 [...]
Novo Nordisk A/S - share repurchase programme
27/07/2026
Bagsværd, Denmark, 27 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Vireo Growth Inc. to Acquire Planet 13 Holdings Inc.
27/07/2026
Transaction expected to deepen Vireo's positions in Nevada and Florida, complement its growing Illinois platform, and further strengthen one of the industry's broadest multi-state cannabis operating platforms [...]
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
27/07/2026
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients – – Activity compares favorably with [...]
Cato Healthcare Supply Appoints Ryan F. Zackon as President and Chief Executive Officer
27/07/2026
Experienced Supply Chain Leader Strengthens Executive Leadership Team to Accelerate Growth, Innovation, and International Expansion DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- Cato Healthcare Supply, a leading healthcare [...]
Flourish Health Raises $46M to Scale Intensive Mental Health Care for Youth in Crisis
27/07/2026
Funding fuels national expansion of model that delivers proven outcomes for high-acuity kids through psychiatrist-led Care Pods and an AI-enabled care delivery platform RICHMOND, Va., July 27, 2026 (GLOBE NEWSWIRE) -- [...]
Cristcot Presents Poster and Select Oral Presentation for Implementing Endocrine Principles to Assess Safety and Compliance within a Clinical Trial at ENDO 2026
27/07/2026
-- Study findings create a framework of protocols for implementing endocrine principles to assess compliance within a clinical trial that can be deployed across medical specialties -- -- Building in hypothalamic- [...]
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update
27/07/2026
Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ , is pleased to share this update on the meaningful advancements the [...]
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
27/07/2026
The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral [...]
NewGen to Acquire Additional 3% of K25.ai at US$250 Million Valuation Following Strong Community Beta; Strengthening Market Cap Above US$5 Million
27/07/2026
Follow-on investment would increase NewGen’s aggregate ownership to 13% BANGKOK, July 27, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified [...]
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
27/07/2026
Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced [...]
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
27/07/2026
TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its board of directors has made a decision to target the agentic artificial intelligence [...]
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
27/07/2026
SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended patient follow-up [...]
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
27/07/2026
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a [...]
Pluristyx Partners With Leading Regenerative Medicine and Aerospace Pioneers to Standardize Clinical-Grade Hepatocyte Manufacturing for Space and Earth Applications
27/07/2026
SEATTLE and WINSTON-SALEM, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Pluristyx, Inc., a leading provider of advanced induced pluripotent stem cell (iPSC) technologies and proprietary, genetically engineered solutions, and [...]
Sofwave to Participate in 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
27/07/2026
SAN CLEMENTE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today [...]
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
27/07/2026
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Charles [...]
ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division
27/07/2026
Lumara Bio brings together ITM's existing pipeline of early- and late-stage radiopharmaceutical therapies, including lead drug candidate 177 Lu-edotreotide (ITM-11), into a single, dedicated division New drug [...]
Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant
27/07/2026
Exclusive agreement with Jamjoom Pharma covers commercialization and distribution of QUVIVIQ™ (daridorexant) in Saudi Arabia and the Levant region Allschwil, Switzerland – July 27, 2026 Idorsia Ltd (SIX: IDIA) has [...]

Pages